Bridging Translational Research to the Clinical Management of Metastatic Breast Cancer

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 4232

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Medicine, University of Udine, Udine, Italy
2. Department of Medical Oncology, CRO Aviano National Cancer Institute, Aviano, Italy
Interests: translational trials; breast cancer; ctDNA; CTC; circulating biomarkers; endocrine resistance; DNA repair; clinical methodology
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
ASUFC University Hospital, Udine, Italy
Interests: breast cancer

E-Mail Website
Guest Editor
Department of Oncology, Haematology and Respiratory Disease, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy
Interests: gynecologic oncology; breast cancer

Special Issue Information

Dear Colleagues,

As new multi-omics technologies are emerging as important tools to support precision medicine, their clinical deployment and feasibility are still greatly debated.

As a matter of fact, to be effectively deployed in the clinic, these approaches need to be scalable, reproducible and with optimized turnaround times. Moreover, the resulting data need to be integrated and interpretable by the clinician both to inform the therapeutic strategy and to enable the development of new clinical trial designs that can validate and take full advantage of these technologies.

This Special Issue is aimed at collecting articles of computational, experimental, translational or statistical nature, aiming at optimizing and translating groundbreaking research approaches to the bedside with a significant impact on clinical utility, such as:

  • Development and validation of machine learning methods to integrate clinical and multi-omits data for the optimization of clinical workflows;
  • Optimization of molecular characterization workflows aimed at clinical scalability;
  • New methodological approaches for biomarker-driven clinical trial designs;
  • Development of new biomarker-driven healthcare workflows;
  • New data science approaches for the real-time integration of multi-omics data streams generated in the clinical environment;
  • Integrated pre-clinical and translational studies aimed at developing new treatment or diagnostic approaches.

Dr. Lorenzo Gerratana
Dr. Marta Bonotto
Dr. Angela Toss
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • translational
  • therapy
  • computational
  • clinical methodology
  • clinical trial design
  • biomarker

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 4118 KiB  
Article
NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
by Yu Cheon Kim, Clara Yuri Kim, Ji Hoon Oh and Myoung Hee Kim
Cells 2021, 10(7), 1633; https://doi.org/10.3390/cells10071633 - 29 Jun 2021
Cited by 12 | Viewed by 3497
Abstract
Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in therapeutic challenges. NR4A1 plays key roles in processes associated with carcinogenesis, apoptosis, DNA [...] Read more.
Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in therapeutic challenges. NR4A1 plays key roles in processes associated with carcinogenesis, apoptosis, DNA repair, proliferation, and inflammation. However, the role of NR4A1 in tamoxifen-resistant ER-positive breast cancer has not yet been elucidated. Here, we propose that NR4A1 is a promising target to overcome tamoxifen resistance. NR4A1 gene expression was downregulated in tamoxifen-resistant MCF7 (TamR) cells compared to that in MCF7 cells. Kaplan-Meier plots were used to identify high NR4A1 expression correlated with increased survival rates in patients with ER-positive breast cancer following tamoxifen treatment. Gain and loss of function experiments showed that NR4A1 restores sensitivity to tamoxifen by regulating cell proliferation, migration, invasion, and apoptosis. NR4A1 localized to the cytoplasm enhanced the expression of apoptotic factors. In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance. These results indicate that NR4A1 could be a potential therapeutic target to overcome tamoxifen resistance in ER-positive breast cancer. Full article
Show Figures

Figure 1

Back to TopTop